NCT Number: NCT03129139
Phase: Phase 1
Trial Summary: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Minneamrita Therapeutics LLC
Acronym: Minnelide 101
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideâ„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives